Key Points

  • Within days after anti-PD1 treatment, HRSCs disappear from the tissue, and the TME is altered.

  • In contrast to solid tumors, no cytotoxic T-cell immune response is detectable.

Abstract

Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to antibodies targeting programmed cell death protein 1 (PD1) and is characterized by scarce Hodgkin and Reed-Sternberg cells (HRSCs), perpetuating a unique tumor microenvironment (TME). Although anti-PD1 effects appear to be largely mediated by cytotoxic CD8+ T cells in solid tumors, HRSCs frequently lack major histocompatibility complex expression, and the mechanism of anti-PD1 efficacy in cHL is unclear. Rapid clinical responses and high interim complete response rates to anti-PD1 based first-line treatment were recently reported for patients with early-stage unfavorable cHL treated in the German Hodgkin Study Group phase 2 NIVAHL trial. To investigate the mechanisms underlying this very early response to anti-PD1 treatment, we analyzed paired biopsies and blood samples obtained from NIVAHL patients before and during the first days of nivolumab first-line cHL therapy. Mirroring the rapid clinical response, HRSCs had disappeared from the tissue within days after the first nivolumab application. The TME already shows a reduction in type 1 regulatory T cells and PD-L1+ tumor-associated macrophages at this early time point of treatment. Interestingly, a cytotoxic immune response and a clonal T-cell expansion were not observed in the tumors or peripheral blood. These early changes in the TME were distinct from alterations found in a separate set of cHL biopsies at relapse during anti-PD1 therapy. We identify a unique very early histologic response pattern to anti-PD1 therapy in cHL that is suggestive of withdrawal of prosurvival factors, rather than induction of an adaptive antitumor immune response, as the main mechanism of action.

REFERENCES

1.
Jachimowicz
RD
,
Pieper
L
,
Reinke
S
, et al
.
Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP [published online ahead of print 7 May 2020]
.
Haematologica
.
2.
Küppers
R
,
Engert
A
,
Hansmann
ML
.
Hodgkin lymphoma
.
J Clin Invest
.
2012
;
122
(
10
):
3439
-
3447
.
3.
Kline
J
,
Godfrey
J
,
Ansell
SM
.
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
.
Blood
.
2020
;
135
(
8
):
523
-
533
.
4.
Roemer
MG
,
Advani
RH
,
Ligon
AH
, et al
.
PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome
.
J Clin Oncol
.
2016
;
34
(
23
):
2690
-
2697
.
5.
Armand
P
,
Engert
A
,
Younes
A
, et al
.
Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial [published correction appears in J Clin Oncol. 2018;36(26):2748]
.
J Clin Oncol
.
2018
;
36
(
14
):
1428
-
1439
.
6.
Younes
A
,
Santoro
A
,
Shipp
M
, et al
.
Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
.
Lancet Oncol
.
2016
;
17
(
9
):
1283
-
1294
.
7.
Ansell
SM
,
Lesokhin
AM
,
Borrello
I
, et al
.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma
.
N Engl J Med
.
2015
;
372
(
4
):
311
-
319
.
8.
Bröckelmann
PJ
,
Goergen
H
,
Keller
U
, et al
.
Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
.
JAMA Oncol
.
2020
;
6
(
6
):
872
-
880
.
9.
Roemer
MGM
,
Redd
RA
,
Cader
FZ
, et al
.
Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma
.
J Clin Oncol
.
2018
;
36
(
10
):
942
-
950
.
10.
Huang
AC
,
Orlowski
RJ
,
Xu
X
, et al
.
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
.
Nat Med
.
2019
;
25
(
3
):
454
-
461
.
11.
Yost
KE
,
Satpathy
AT
,
Wells
DK
, et al
.
Clonal replacement of tumor-specific T cells following PD-1 blockade
.
Nat Med
.
2019
;
25
(
8
):
1251
-
1259
.
12.
Sasse
S
,
Reddemann
K
,
Diepstra
A
, et al
.
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
.
Haematologica
.
2019
;
104
(
1
):
e21
-
e24
.
13.
Schnitter
A
,
Kohler
CW
,
Reddemann
K
, et al
.
Therapeutic targets and microenvironment in sequential biopsies of classical Hodgkin lymphoma at diagnosis and relapse
.
J Hematop
.
2019
;
12
(
1
):
11
-
17
.
14.
Nijland
M
,
Veenstra
RN
,
Visser
L
, et al
.
HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy?
OncoImmunology
.
2017
;
6
(
4
):
e1295202
.
15.
Schmitz
C
,
Rekowski
J
,
Reinke
S
, et al
.
Metabolic tumor volume, cancer cell fraction, and prognosis - the case of T-cell/histiocyte-rich large B-cell lymphoma
.
Leuk Lymphoma
.
2020
;
61
(
6
):
1372
-
1379
.
16.
Masqué-Soler
N
,
Szczepanowski
M
,
Kohler
CW
,
Spang
R
,
Klapper
W
.
Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens
.
Blood
.
2013
;
122
(
11
):
1985
-
1986
.
17.
Brüggemann
M
,
Kotrová
M
,
Knecht
H
, et al;
EuroClonality-NGS working group
.
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
.
Leukemia
.
2019
;
33
(
9
):
2241
-
2253
.
18.
Knecht
H
,
Reigl
T
,
Kotrová
M
, et al;
EuroClonality-NGS Working Group
.
Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
.
Leukemia
.
2019
;
33
(
9
):
2254
-
2265
.
19.
Bystry
V
,
Reigl
T
,
Krejci
A
, et al;
EuroClonality-NGS
.
ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data
.
Bioinformatics
.
2017
;
33
(
3
):
435
-
437
.
20.
Voltin
C-A
,
Mettler
J
,
van Heek
L
, et al
.
Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial l [published online ahead of print 29 October 2020]
.
Clin Cancer Res
.
doi:10.1158/1078-0432.CCR-20-3303 Published ahead of print
21.
Stein
JE
,
Soni
A
,
Danilova
L
, et al
.
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
.
Ann Oncol
.
2019
;
30
(
4
):
589
-
596
.
22.
Valpione
S
,
Galvani
E
,
Tweedy
J
, et al
.
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
.
Nat Can
.
2020
;
1
(
2
):
210
-
221
.
23.
Ma
Y
,
Visser
L
,
Roelofsen
H
, et al
.
Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes
.
Blood
.
2008
;
111
(
4
):
2339
-
2346
.
24.
Aoki
T
,
Chong
LC
,
Takata
K
, et al
.
Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma
.
Cancer Discov
.
2020
;
10
(
3
):
406
-
421
.
25.
Cader
FZ
,
Schackmann
RCJ
,
Hu
X
, et al
.
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment
.
Blood
.
2018
;
132
(
8
):
825
-
836
.
26.
Tumeh
PC
,
Harview
CL
,
Yearley
JH
, et al
.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
.
Nature
.
2014
;
515
(
7528
):
568
-
571
.
27.
Cader
FZ
,
Hu
X
,
Goh
WL
, et al
.
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
.
Nat Med
.
2020
;
26
(
9
):
1468
-
1479
.
28.
Jalali
S
,
Price-Troska
T
,
Bothun
C
, et al
.
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
.
Blood Cancer J
.
2019
;
9
(
3
):
22
.
29.
Taylor
JG
,
Clear
A
,
Calaminici
M
,
Gribben
JG
.
Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy
.
Haematologica
.
2019
;
104
(
1
):
e42
-
e44
.
30.
Carey
CD
,
Gusenleitner
D
,
Lipschitz
M
, et al
.
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
.
Blood
.
2017
;
130
(
22
):
2420
-
2430
.
31.
Arlt
A
,
von Bonin
F
,
Rehberg
T
, et al
.
High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination
.
Mol Oncol
.
2020
;
14
(
3
):
571
-
589
.
32.
Chan
FC
,
Mottok
A
,
Gerrie
AS
, et al
.
Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma
.
J Clin Oncol
.
2017
;
35
(
32
):
3722
-
3733
.
You do not currently have access to this content.

Sign in via your Institution

Sign In